Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.

Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, Chebib M, McGregor IS, Arnold JC.

Epilepsia. 2019 Oct 17. doi: 10.1111/epi.16355. [Epub ahead of print]

PMID:
31625159
2.

Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors.

Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M.

Cannabis Cannabinoid Res. 2019 Sep 23;4(3):165-176. doi: 10.1089/can.2019.0016. eCollection 2019.

3.

Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices.

Arkell TR, Kevin RC, Stuart J, Lintzeris N, Haber PS, Ramaekers JG, McGregor IS.

Drug Test Anal. 2019 Oct;11(10):1486-1497. doi: 10.1002/dta.2687. Epub 2019 Sep 10.

PMID:
31442003
4.

Cannabichromene is a cannabinoid CB2 receptor agonist.

Udoh M, Santiago M, Devenish S, McGregor IS, Connor M.

Br J Pharmacol. 2019 Aug 1. doi: 10.1111/bph.14815. [Epub ahead of print]

PMID:
31368508
5.

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist.

Kevin RC, Anderson L, McGregor IS, Boyd R, Manning JJ, Glass M, Connor M, Banister SD.

Front Pharmacol. 2019 May 29;10:595. doi: 10.3389/fphar.2019.00595. eCollection 2019.

6.

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS.

Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724. doi: 10.1007/s00213-019-05246-8. Epub 2019 May 1.

7.

The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs.

Banister SD, Kevin RC, Martin L, Adams A, Macdonald C, Manning JJ, Boyd R, Cunningham M, Stevens MY, McGregor IS, Glass M, Connor M, Gerona RR.

Drug Test Anal. 2019 Jul;11(7):976-989. doi: 10.1002/dta.2583. Epub 2019 May 8.

PMID:
30838752
8.

Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic.

Absalom NL, Ahring PK, Liao VW, Balle T, Jiang T, Anderson LL, Arnold JC, McGregor IS, Bowen MT, Chebib M.

J Biol Chem. 2019 Apr 12;294(15):6157-6171. doi: 10.1074/jbc.RA118.005697. Epub 2019 Feb 6.

PMID:
30728247
9.

Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

PMID:
30705707
10.

Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.

Banister SD, Arnold JC, Connor M, Glass M, McGregor IS.

ACS Chem Neurosci. 2019 May 15;10(5):2160-2175. doi: 10.1021/acschemneuro.8b00651. Epub 2019 Feb 22.

PMID:
30689342
11.

Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.

Gamage TF, Farquhar CE, McKinnie RJ, Kevin RC, McGregor IS, Trudell ML, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2019 Mar;368(3):414-422. doi: 10.1124/jpet.118.254425. Epub 2018 Dec 14.

PMID:
30552295
12.

Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats.

Hay GL, Baracz SJ, Everett NA, Roberts J, Costa PA, Arnold JC, McGregor IS, Cornish JL.

J Psychopharmacol. 2018 Dec;32(12):1369-1378. doi: 10.1177/0269881118799954. Epub 2018 Sep 27.

PMID:
30260267
13.

Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.

Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Vilamala MV, Lladanosa CG, Barratt MJ, Gerona RR.

Drug Test Anal. 2019 Feb;11(2):279-291. doi: 10.1002/dta.2491. Epub 2018 Oct 1.

PMID:
30151911
14.

Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16).

Lintzeris N, Driels J, Elias N, Arnold JC, McGregor IS, Allsop DJ.

Med J Aust. 2018 Aug 3;209(5):211-216. Epub 2018 Aug 13.

PMID:
30092752
15.

Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Aug 2;8(1):11850. doi: 10.1038/s41598-018-30164-8.

16.

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Jul 5;8(1):10154. doi: 10.1038/s41598-018-28127-0. Erratum in: Sci Rep. 2018 Aug 2;8(1):11850.

17.

Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey.

Karanges EA, Suraev A, Elias N, Manocha R, McGregor IS.

BMJ Open. 2018 Jul 3;8(7):e022101. doi: 10.1136/bmjopen-2018-022101.

18.

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.

Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group.

BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2.

19.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

20.

The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement.

Everett NA, McGregor IS, Baracz SJ, Cornish JL.

Neuropharmacology. 2018 May 1;133:1-11. doi: 10.1016/j.neuropharm.2017.12.036. Epub 2018 Jan 17.

PMID:
29353054
21.

The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs.

Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M.

Drug Test Anal. 2018 Jan 19. doi: 10.1002/dta.2362. [Epub ahead of print]

PMID:
29350472
22.

Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding.

Russell J, Maguire S, Hunt GE, Kesby A, Suraev A, Stuart J, Booth J, McGregor IS.

Psychoneuroendocrinology. 2018 Jan;87:83-92. doi: 10.1016/j.psyneuen.2017.10.014. Epub 2017 Oct 14.

PMID:
29049935
23.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

24.

In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

25.

Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues.

Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2017 Oct 18;8(10):2159-2167. doi: 10.1021/acschemneuro.7b00267. Epub 2017 Aug 11.

PMID:
28792725
26.

Biologically meaningful scents: a framework for understanding predator-prey research across disciplines.

Parsons MH, Apfelbach R, Banks PB, Cameron EZ, Dickman CR, Frank ASK, Jones ME, McGregor IS, McLean S, Müller-Schwarze D, Sparrow EE, Blumstein DT.

Biol Rev Camb Philos Soc. 2018 Feb;93(1):98-114. doi: 10.1111/brv.12334. Epub 2017 Apr 26. Review.

PMID:
28444848
27.

The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors.

Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M.

Pharmacol Res. 2017 May;119:358-370. doi: 10.1016/j.phrs.2017.02.022. Epub 2017 Feb 27.

PMID:
28249817
28.

An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use.

Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS, Ireland C, Lintzeris N.

Epilepsy Behav. 2017 May;70(Pt B):334-340. doi: 10.1016/j.yebeh.2017.02.005. Epub 2017 Feb 24.

29.

Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.

Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M, McGregor IS.

J Psychopharmacol. 2017 Jun;31(6):757-769. doi: 10.1177/0269881116684336. Epub 2017 Jan 16.

PMID:
28093016
30.

Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059.

Hicks C, Ramos L, Dampney B, Baracz SJ, McGregor IS, Hunt GE.

Brain Res Bull. 2016 Oct;127:208-218. doi: 10.1016/j.brainresbull.2016.10.005. Epub 2016 Oct 8.

PMID:
27725169
31.

MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors.

Ramos L, Hicks C, Caminer A, Couto K, Narlawar R, Kassiou M, McGregor IS.

Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:115-123. doi: 10.1016/j.pbb.2016.10.002. Epub 2016 Oct 7.

PMID:
27725273
32.

Behavioral and cognitive data in mice with different tryptophan-metabolizing enzymes knocked out.

Too LK, Li KM, Suarna C, Maghzal GJ, Stocker R, McGregor IS, Hunt NH.

Data Brief. 2016 Sep 6;9:275-87. doi: 10.1016/j.dib.2016.08.071. eCollection 2016 Dec.

33.

Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia.

Clarke DJ, Stuart J, McGregor IS, Arnold JC.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:9-15. doi: 10.1016/j.pnpbp.2016.08.006. Epub 2016 Aug 10.

PMID:
27521758
34.

Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.

Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M.

ACS Chem Neurosci. 2016 Sep 21;7(9):1241-54. doi: 10.1021/acschemneuro.6b00137. Epub 2016 Jul 27.

PMID:
27421060
35.

Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.

Too LK, Li KM, Suarna C, Maghzal GJ, Stocker R, McGregor IS, Hunt NH.

Behav Brain Res. 2016 Oct 1;312:102-17. doi: 10.1016/j.bbr.2016.06.018. Epub 2016 Jun 15.

PMID:
27316339
36.

ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice.

Brzozowska N, Li KM, Wang XS, Booth J, Stuart J, McGregor IS, Arnold JC.

PeerJ. 2016 May 26;4:e2081. doi: 10.7717/peerj.2081. eCollection 2016.

37.

Antibody-induced neutrophil depletion prior to the onset of pneumococcal meningitis influences long-term neurological complications in mice.

Too LK, Mitchell AJ, McGregor IS, Hunt NH.

Brain Behav Immun. 2016 Aug;56:68-83. doi: 10.1016/j.bbi.2016.01.021. Epub 2016 Mar 7.

PMID:
26965652
38.

Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine.

Karanges EA, Ramos L, Dampney B, Suraev AS, Li KM, McGregor IS, Hunt GE.

Brain Res Bull. 2016 Mar;121:246-54. doi: 10.1016/j.brainresbull.2016.02.008. Epub 2016 Feb 11.

PMID:
26876759
39.

Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens.

Peters ST, Bowen MT, Bohrer K, McGregor IS, Neumann ID.

Addict Biol. 2017 May;22(3):702-711. doi: 10.1111/adb.12362. Epub 2016 Jan 25.

PMID:
26810371
40.

Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain.

Kashem MA, Ahmed S, Sultana N, Ahmed EU, Pickford R, Rae C, Šerý O, McGregor IS, Balcar VJ.

Neurochem Res. 2016 Feb;41(1-2):385-97. doi: 10.1007/s11064-016-1830-3. Epub 2016 Jan 22.

PMID:
26801172
41.

Altered behaviour and cognitive function following combined deletion of Toll-like receptors 2 and 4 in mice.

Too LK, McGregor IS, Baxter AG, Hunt NH.

Behav Brain Res. 2016 Apr 15;303:1-8. doi: 10.1016/j.bbr.2016.01.024. Epub 2016 Jan 13.

PMID:
26774978
42.

Chronic Methamphetamine Self-Administration Dysregulates Oxytocin Plasma Levels and Oxytocin Receptor Fibre Density in the Nucleus Accumbens Core and Subthalamic Nucleus of the Rat.

Baracz SJ, Parker LM, Suraev AS, Everett NA, Goodchild AK, McGregor IS, Cornish JL.

J Neuroendocrinol. 2016 Apr;28(4). doi: 10.1111/jne.12337.

PMID:
26563756
43.

Cortisol response and psychological distress predict susceptibility to false memories for a trauma film.

Monds LA, Paterson HM, Ali S, Kemp RI, Bryant RA, McGregor IS.

Memory. 2016 Oct;24(9):1278-86. doi: 10.1080/09658211.2015.1102287. Epub 2015 Oct 23.

PMID:
26493075
44.

The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence.

Allsop DJ, Bartlett DJ, Johnston J, Helliwell D, Winstock A, McGregor IS, Lintzeris N.

J Clin Sleep Med. 2015 Oct 15;11(10):1153-62. doi: 10.5664/jcsm.5090.

45.

Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.

Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59. doi: 10.1021/acschemneuro.5b00112. Epub 2015 Jul 17.

PMID:
26134475
46.

Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.

Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Aug 19;6(8):1445-58. doi: 10.1021/acschemneuro.5b00107. Epub 2015 May 8.

PMID:
25921407
47.

Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.

Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS.

Clin Pharmacol Ther. 2015 Jun;97(6):571-4. doi: 10.1002/cpt.109. Epub 2015 Apr 17. Review.

PMID:
25777582
48.

Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.

Ramos L, Hicks C, Caminer A, Goodwin J, McGregor IS.

Psychopharmacology (Berl). 2015 Jul;232(14):2631-41. doi: 10.1007/s00213-015-3899-9. Epub 2015 Mar 15.

PMID:
25772337
49.

WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action.

Hicks C, Ramos L, Reekie TA, Narlawar R, Kassiou M, McGregor IS.

Psychopharmacology (Berl). 2015 Aug;232(15):2659-67. doi: 10.1007/s00213-015-3902-5. Epub 2015 Mar 13.

PMID:
25761839
50.

Oxytocin prevents ethanol actions at δ subunit-containing GABAA receptors and attenuates ethanol-induced motor impairment in rats.

Bowen MT, Peters ST, Absalom N, Chebib M, Neumann ID, McGregor IS.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):3104-9. doi: 10.1073/pnas.1416900112. Epub 2015 Feb 23.

Supplemental Content

Loading ...
Support Center